Email updates

Keep up to date with the latest news and content from BMC Complementary and Alternative Medicine and BioMed Central.

Open Access Open Badges Research article

Astragalus membranaceus up-regulate Cosmc expression and reverse IgA dys-glycosylation in IgA nephropathy

Ling Ji1, XiaoLei Chen1, Xiang Zhong2, Zi Li1, Lichuan Yang1, Junming Fan13, Wanxing Tang1 and Wei Qin1*

Author Affiliations

1 Division of Nephrology, Department of Medicine, West China Hospital of Sichuan University, 37 # Guoxue road, Wuhou District, Chengdu, Sichuan, China

2 Division of Nephrology, Sichuan Provincial People’s Hospital, Chengdu, Sichuan, China

3 State Key Laboratory of Biotherapy of Sichuan University, Chengdu, Sichuan, China

For all author emails, please log on.

BMC Complementary and Alternative Medicine 2014, 14:195  doi:10.1186/1472-6882-14-195

Published: 18 June 2014



Decreased Core I β3-Gal-T-specific molecular chaperone (Cosmc) expression induced IgA1 aberrant glycosylation is the main characteristic of IgA nephropathy (IgAN). This study tried to elucidate the effect of Astragalus membranaceus on Cosmc expression and IgA O-glycosylation of peripheral B lymphocytes in IgAN patients.


Peripheral B lymphocytes of 21 IgAN patients and 10 normal controls were isolated and cultured with or without lipopolysaccharide (LPS) and Astragalus membranaceus injection (AMI). Cosmc mRNA and protein expression levels were measured by real-time RT-PCR and Western blot. IgA1 and glycosylation level were determined by enzyme-linked immunosorbent assay (ELISA) and VV lectin-binding method.


Cosmc mRNA expression and IgA1 O-glycosylation level in IgAN patients was significantly lower than normal controls at baseline. Treatment of LPS could obviously inhibit Cosmc expression and increase the IgA1 secretion in peripheral B lymphocytes of IgAN patients, which resulted in a significantly increase in IgA1 aberrant glycosylation level. Addition of AMI could remarkably up regulated Cosmc expression, decrease IgA1 secretion, and reverse glycosylation level in a dose related manner.


AMI can up-regulate Cosmc expression of peripheral B lymphocytes and reverse IgA1 aberrant O-glycosylation level, which might be the underlying mechanism of AMI therapy in treating IgAN.

Trial registration

TCTR20140515001 (Registration Date: 2014-05-15)

IgA nephropathy; Astragalus membranaceus; Cosmc; Glycosylation